Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant

  • Nelson Leung
    Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN;
  • Frank Bridoux
    Department of Nephrology and Transplantation, University Hospital Poitiers, Poitiers, France;
  • Colin A. Hutchison
    Renal Institute of Birmingham, University Hospital Birmingham and University of Birmingham, Birmingham, United Kingdom;
  • Samih H. Nasr
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN;
  • Paul Cockwell
    Renal Institute of Birmingham, University Hospital Birmingham and University of Birmingham, Birmingham, United Kingdom;
  • Jean-Paul Fermand
    Univerisity Hospital St Louis, Paris, Ile De France, France; and
  • Angela Dispenzieri
    Division of Hematology, Mayo Clinic, Rochester, MN;
  • Kevin W. Song
    Division of Hematology, Vancouver General Hospital, Vancouver, BC
  • Robert A. Kyle
    Division of Hematology, Mayo Clinic, Rochester, MN;

抄録

<jats:title>Abstract</jats:title><jats:p>Multiple myeloma is the most frequent monoclonal gammopathy to involve the kidney; however, a growing number of kidney diseases associated with other monoclonal gammopathies are being recognized. Although many histopathologic patterns exist, they are all distinguished by the monoclonal immunoglobulin (or component) deposits. The hematologic disorder in these patients is more consistent with monoclonal gammopathy of undetermined significance (MGUS) than with multiple myeloma. Unfortunately, due to the limitations of the current diagnostic schema, they are frequently diagnosed as MGUS. Because treatment is not recommended for MGUS, appropriate therapy is commonly withheld. In addition to end-stage renal disease, the persistence of the monoclonal gammopathy is associated with high rates of recurrence after kidney transplantation. Preservation and restoration of kidney function are possible with successful treatment targeting the responsible clone. Achievement of hematologic complete response has been shown to prevent recurrence after kidney transplantation. There is a need for a term that properly conveys the pathologic nature of these diseases. We think the term monoclonal gammopathy of renal significance is most helpful to indicate a causal relationship between the monoclonal gammopathy and the renal damage and because the significance of the monoclonal gammopathy is no longer undetermined.</jats:p>

収録刊行物

  • Blood

    Blood 120 (22), 4292-4295, 2012-11-22

    American Society of Hematology

被引用文献 (10)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ